Cargando…
Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer
Breathlessness is among the most common and deteriorating symptoms in patients with advanced cancer, which may worsen towards the end of life. Breathlessness in patients with estimated life expectancy of weeks to days has unique clinical features: it tends to worsen rapidly over days to hours as dea...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046422/ https://www.ncbi.nlm.nih.gov/pubmed/33558034 http://dx.doi.org/10.1136/esmoopen-2019-000603 |
_version_ | 1783501949909336064 |
---|---|
author | Mori, Masanori Yamaguchi, Takashi Matsuda, Yoshinobu Suzuki, Kozue Watanabe, Hiroaki Matsunuma, Ryo Kako, Jun Imai, Kengo Usui, Yuko Matsumoto, Yoshihisa Hui, David Currow, David Morita, Tatsuya |
author_facet | Mori, Masanori Yamaguchi, Takashi Matsuda, Yoshinobu Suzuki, Kozue Watanabe, Hiroaki Matsunuma, Ryo Kako, Jun Imai, Kengo Usui, Yuko Matsumoto, Yoshihisa Hui, David Currow, David Morita, Tatsuya |
author_sort | Mori, Masanori |
collection | PubMed |
description | Breathlessness is among the most common and deteriorating symptoms in patients with advanced cancer, which may worsen towards the end of life. Breathlessness in patients with estimated life expectancy of weeks to days has unique clinical features: it tends to worsen rapidly over days to hours as death approaches often despite current symptom control measures. Breathlessness in patients during the last weeks to days of life can be called ‘terminal breathlessness’. While evidence has accumulated for the management of breathlessness in patients with cancer who are not dying, such evidence may not be fully applied to terminal breathlessness. Only a few studies have investigated the best practice of terminal breathlessness in patients with cancer. In this paper, we summarise the current evidence for the management of terminal breathlessness, and propose future directions of clinical research. |
format | Online Article Text |
id | pubmed-7046422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-70464222020-03-09 Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer Mori, Masanori Yamaguchi, Takashi Matsuda, Yoshinobu Suzuki, Kozue Watanabe, Hiroaki Matsunuma, Ryo Kako, Jun Imai, Kengo Usui, Yuko Matsumoto, Yoshihisa Hui, David Currow, David Morita, Tatsuya ESMO Open Review Breathlessness is among the most common and deteriorating symptoms in patients with advanced cancer, which may worsen towards the end of life. Breathlessness in patients with estimated life expectancy of weeks to days has unique clinical features: it tends to worsen rapidly over days to hours as death approaches often despite current symptom control measures. Breathlessness in patients during the last weeks to days of life can be called ‘terminal breathlessness’. While evidence has accumulated for the management of breathlessness in patients with cancer who are not dying, such evidence may not be fully applied to terminal breathlessness. Only a few studies have investigated the best practice of terminal breathlessness in patients with cancer. In this paper, we summarise the current evidence for the management of terminal breathlessness, and propose future directions of clinical research. BMJ Publishing Group 2020-02-04 /pmc/articles/PMC7046422/ /pubmed/33558034 http://dx.doi.org/10.1136/esmoopen-2019-000603 Text en © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Mori, Masanori Yamaguchi, Takashi Matsuda, Yoshinobu Suzuki, Kozue Watanabe, Hiroaki Matsunuma, Ryo Kako, Jun Imai, Kengo Usui, Yuko Matsumoto, Yoshihisa Hui, David Currow, David Morita, Tatsuya Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer |
title | Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer |
title_full | Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer |
title_fullStr | Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer |
title_full_unstemmed | Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer |
title_short | Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer |
title_sort | unanswered questions and future direction in the management of terminal breathlessness in patients with cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046422/ https://www.ncbi.nlm.nih.gov/pubmed/33558034 http://dx.doi.org/10.1136/esmoopen-2019-000603 |
work_keys_str_mv | AT morimasanori unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT yamaguchitakashi unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT matsudayoshinobu unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT suzukikozue unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT watanabehiroaki unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT matsunumaryo unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT kakojun unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT imaikengo unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT usuiyuko unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT matsumotoyoshihisa unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT huidavid unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT currowdavid unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer AT moritatatsuya unansweredquestionsandfuturedirectioninthemanagementofterminalbreathlessnessinpatientswithcancer |